Continuing Education Activity

Beta-2 adrenergic receptor agonists are a cornerstone in managing asthma and chronic obstructive pulmonary disease, functioning as potent bronchodilators that alleviate airflow obstruction and improve respiratory function. These agents stimulate beta-2 adrenergic receptors in bronchial smooth muscle, leading to cyclic adenosine monophosphate–mediated relaxation and airway dilation. Short-acting beta-2 agonists rapidly relieve acute bronchospasm, whereas long-acting formulations maintain symptom control and reduce exacerbation frequency. Despite proven efficacy, challenges remain regarding optimal dosing, variable patient response, and the potential for adverse effects such as tachycardia, tremor, hypokalemia, and paradoxical bronchospasm. Tolerance may develop with chronic use, emphasizing the need for individualized therapy and adherence to evidence-based treatment algorithms. Understanding the pharmacodynamics, receptor selectivity, and interactions of beta-2 agonists enhances therapeutic precision and promotes safer respiratory care.

Through participation in this educational activity, the learner develops enhanced competence in the pharmacologic principles, clinical applications, and safety considerations of beta-2 adrenergic receptor agonists. The curriculum reinforces best practices in selecting appropriate agents, optimizing dosage regimens, and monitoring for therapeutic efficacy and adverse reactions. Collaboration among clinicians, respiratory therapists, pharmacists, and nursing professionals ensures coordinated, patient-centered care through integrated assessment, education, and follow-up. Interprofessional teamwork facilitates early recognition of complications, supports individualized treatment adjustments, and promotes adherence to established guidelines. This course enhances safety, efficacy, and overall outcomes for patients receiving beta-2 adrenergic receptor agonist therapy by strengthening clinical decision-making and communication across disciplines.

Objectives:

• Identify the function and key concepts of beta-2 adrenergic receptor agonists.
• Evaluate the issues of concern regarding beta-2 adrenergic receptor agonists.
• Apply best practices when evaluating the clinical significance of beta-2 adrenergic receptor agonists.
• Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from beta-2 adrenergic receptor agonists therapy.

Introduction

Beta-2 adrenergic agonists are used as a mainstay treatment for respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). They replicate the functions of catecholamines, such as epinephrine, norepinephrine, and dopamine, in producing various autonomic responses within the body. Specifically, the smooth muscle of the airway, uterus, intestine, and systemic vasculature are areas where beta-2 agonists have the most significant effect. Thus, the focus of development for this drug class has been primarily on the clinical implications related to their ability to affect the target organ systems. Over the last century, extensive research has been conducted on these drugs' bronchodilatory and anti-bronchoconstrictive properties.

The early 1900s marked the advent of epinephrine as a form of treatment in Western medicine, following its successful extraction from the adrenal gland. This became the standard treatment for patients with asthma until it was replaced in the 1940s with the introduction of isoproterenol, a nonselective beta-adrenergic receptor agonist. However, the adverse effects of isoproterenol became an issue of concern, and the search continued for a treatment with a better adverse effect profile. With the discovery of the alpha-1, alpha-2, beta-1, and beta-2 receptors in subsequent years, it became known that airway bronchodilation had a strong correlation specifically with beta-2 receptors in the lung vasculature.

Pharmacological pursuits focused on maximizing selectivity for the beta-2 receptor to reduce the incidence of adverse effects associated with the nonselective isoproterenol. These new drugs, classified as beta-2 adrenergic receptor agonists, have since become frontline treatments for bronchial asthma and COPD. Subsequent research aims to enhance efficacy, minimize adverse effects, alleviate symptoms, decrease mortality rates, and improve patient quality of life.[1] However, since the discovery of beta-2 agonists, there have been many discussions regarding the potential long-term risks versus benefits to the overall rate of morbidity and mortality. This article aims to provide a foundational background on the mechanism of action of beta-2 agonists, their various classifications, and their associated clinical significance; also discussed are areas of concern and speculation regarding this class of medications.

Function

Mechanism of Action

Circulating catecholamines activate adrenergic receptors as part of our functional autonomic system to produce parasympathetic and sympathetic physiological responses. Mimicking catecholamines, beta-2 agonists act as ligands to adrenergic receptors with increased selectivity towards beta-2 adrenergic receptors. Activating the beta-2 adrenergic receptor initiates a transmembrane signal cascade that involves the heterotrimeric G protein Gs and the effector adenylyl cyclase. Adenylyl cyclase then increases intracellular cyclic adenosine monophosphate (cAMP) by catalyzing the hydrolysis of adenosine triphosphate. The elevated cAMP concentration activates cAMP-dependent protein kinase A (PKA). PKA can phosphorylate intracellular substrates, thereby modulating various cellular effects. Specifically, in airway smooth muscle, PKA acts to phosphorylate Gq-coupled receptors, leading to a cascade of intracellular signals proposed to reduce intracellular calcium ions (Ca2+) or decrease the sensitivity of Ca2+ channels.[1] The change in Ca2+ results in the inhibition of myosin light chain phosphorylation, subsequently preventing airway smooth muscle contraction. This action is the underlying mechanism behind beta-2 agonists, which promote the bronchodilatory effects used to treat many common respiratory diseases. There have been proposals that beta-2 agonists also provide anti-inflammatory effects within the airway smooth muscle by reducing intercellular adhesion molecule-1, reducing granulocyte-macrophage colony-stimulating factor release, and stabilizing mast cell degranulation by inhibiting multiple inflammatory pathways.[2]

Classification

Their onset of action and duration determine the classification of beta-2 agonists. The classes separate into short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and, most recently, ultra-long-acting beta-agonists (ultra-LABAs). As the names suggest, SABAs have the shortest half-life and are for immediate symptomatic relief. LABAs and ultra-LABAs offer prolonged and sustained treatment due to their increased half-lives. The differences in properties between these classes arise from modifications to the molecular structure of the drugs. For example, prolonging the duration of action can be achieved by reducing the beta-2 agonist’s susceptibility to catechol O-methyltransferase and monoamine oxidase enzymes, which inactivate the drug through oxidative deamination and methylation.

Short-Acting Beta-Agonists

SABAs are the first-line medications for the acute treatment of asthma symptoms and exacerbations. They are also commonly used with LABAs, inhaled corticosteroids, or long-acting muscarinic antagonists (LAMA) in treating COPD. Typical administration of these agents involves inhalation via metered-dose inhalers or dry powder inhalers. Compared to the alternative oral administration, inhalation has an increase in therapeutic value and a decrease in systemic adverse effects.[2] The hallmark SABA is salbutamol (albuterol), which has an onset of action of under 5 minutes and a therapeutic effect duration of between 3 and 6 hours. While most commonly used as an airway treatment, nebulized albuterol is also helpful for hyperkalemia by providing a rapid shift of intracellular potassium.[3] Terbutaline is used off-label as a tocolytic for short-term suppression of preterm uterine contractions, but prolonged use (>48–72 hours) is not advisable due to maternal cardiovascular risks.[4]

 Common SABAs

• Salbutamol (albuterol)
• Terbutaline
• Levalbuterol
• Pirbuterol

LABAs

LABAs are used to treat patients with asthma and COPD, often in conjunction with inhaled corticosteroids. There is evidence of greater efficacy with dual therapy versus monotherapy with LABA.[5] They have an onset of duration greater than 5 minutes compared to the SABAs, with a duration of up to 15 minutes for salmeterol and a duration of effect of at least 12 hours. Similar to SABAs, the recommended route of administration for LABAs is through inhalation. LABAs are generally added as a second-line treatment in asthma that has failed symptomatic relief with SABAs and inhaled corticosteroids (ICS). However, there is current controversy on using LABA as monotherapy versus dual therapy with ICS, as will be discussed in the topics further below.

Common LABAs

• Salmeterol
• Formoterol
• Arformoterol (enantiomer of formoterol) [6] 

Ultra-LABAs

Ultra-LABAs have the most significant duration of effect, up to 24 hours, and offer the additional benefit of a once-daily treatment dosage. The Food and Drug Administration has approved Indacaterol as a maintenance treatment for patients with COPD and other bronchodilators. Indacaterol is administered as a dry powder with an onset of action of around 5 minutes. Several other ultra-LABAs are currently under research, with the potential to enhance compliance and convenience compared to current options for asthma and COPD treatments.[7]

Common Ultra-LABAS

• Indacaterol
• Olodaterol
• Vilanterol [8] 

Administration

The major routes of administration for beta-2 agonists include metered-dose inhalers, nebulizers, dry powder inhalers, and oral, subcutaneous, or intravenous administration. The preferred route of administration for beta-2 agonists in treating asthma and COPD is through inhalation. Inhalation localizes the drug to the lung tissue, concentrating the therapeutic effect on the airway smooth muscles while minimizing the distribution of the drug to the systemic circulation. There has been no correlation between the therapeutic effect of inhaled beta-2 agonists and the peak plasma levels of the beta-2 agonist.[9] Less frequently, beta-2 agonists are administered orally, which has been shown to cause an increase in systemic adverse effects. The tocolytic terbutaline can also be given intravenously, intramuscularly, or orally.

Issues of Concern

Adverse Effects

Adverse effects of beta-2 agonists most commonly involve the desensitization of the beta-2 adrenergic receptor to the beta-2 agonist. Due to the similar properties between the classes of adrenergic receptors, beta-2 agonists can create an “off-target” effect in stimulating either alpha-1, alpha-2, or beta-1 receptors.[10] The most common adverse effects of beta-2 agonists involve the cardiac, metabolic, or musculoskeletal system. 

Due to the vasodilatory effect on the peripheral vasculature and the subsequent decrease in cardiac venous return, compensatory mechanisms, such as tachycardia, are relatively common, especially within the first weeks of use. Cardiac toxicity in the form of arrhythmias, cardiomyopathy, and ischemia has been correlated more strongly with older-generation beta-2 agonists, according to multiple reports ranging from single case reports to case-control studies.[11] Arrhythmias are more common in patients using fenoterol than albuterol, and they increase in frequency in patients with underlying heart disease or concomitant theophylline use.[12] Beta-2 agonists can lower serum potassium levels by promoting an inward shift of potassium into cells by stimulating the membrane-bound sodium/potassium-adenosine triphosphatase; this mechanism may lead to hypokalemia. Beta-2 agonists also promote glycogenolysis, which can lead to inadvertent elevations in serum glucose. Musculoskeletal tremors are also a potential adverse effect, found more commonly with the use of oral beta-2 agonists.

The degree to which these adverse effects precipitate is generally associated with factors such as the selectivity ability of each beta-2 agonist to its respective receptor and the medication dosages. Several studies' results have also indicated hypoxemia and hypercapnia as exacerbating factors to the cardiotoxic effects of beta-2 agonists.[10] Tremor and palpitations are also common at higher doses.[13] 

Tolerance

Desensitization of the beta-2 receptor due to prolonged stimulation from agonists can lead to tolerance. Tolerance involves blunting both the bronchodilatory and the anti-bronchoconstrictor effects of beta-2 agonists.[14] Results from multiple studies have shown that prolonged use of salbutamol reduces the bronchodilatory response to methacholine-induced airway constriction.[15] However, tolerance's clinical implications for treatment management are still under investigation. Theoretically, LABAs should increase tolerance compared to SABAs due to the continuous beta-receptor stimulation produced from their prolonged duration of action. However, this remains a topic of speculation, as studies have shown varying degrees of tolerance between both SABAs and LABAs.[16][17]  Research has also suggested multiple external factors as influences on the degree of beta-2 agonist tolerance, including genetic polymorphisms of the beta-2 receptor, the degree of airway inflammation, and the route of medication delivery.[18]

Clinical Significance

Asthma and COPD are currently among the most prevalent respiratory diseases in the population. A randomized study in Italy, involving 3000 subjects, examined the prevalence of asthma and COPD. The study's results concluded that 1 in 8 adults older than 20 years was affected by either asthma, COPD, or the co-existence of both diseases.[19]

Treatment and management begin with understanding the symptoms, confirmatory diagnostic tests, and proper assessment of the severity of the conditions. Beta-2 agonists are integral to frontline management for symptomatic control, preventing exacerbations, and improving quality of life. The National Asthma Education and Protection Program has adopted a step-wise approach to treating bronchial asthma, with SABAs as the first-line treatment for mild acute episodes. Stratification of asthma severity is based on the frequency of daytime and nighttime symptoms, the degree of interference with regular activities, and lung function, as measured by the forced expiratory volume in 1 second/forced vital capacity ratio. A moderate or severe persistent asthma warrants additional therapy in the form of inhaled corticosteroids, followed by LABAs.

Additional respiratory therapies may be considered if symptoms persist or worsen. Similarly, the Global Initiative for COPD (GOLD) guidelines outline a systematic approach to treating COPD, which involves assessing the severity of symptoms, identifying risk factors for future exacerbations, and evaluating overall lung function. Beta-2 agonists are once again at the forefront of treatment options. In the case of COPD management according to GOLD guidelines, anticholinergics are often added early, along with beta-2 agonists and inhaled corticosteroids.[20]

Both the National Asthma Education and Prevention Program (NAEPP) 2020 Focused Updates and the Global Initiative for Asthma (GINA) guidelines emphasize a process that involves assessing adherence, inhaler technique, environmental factors, and comorbidities as initial steps. The NAEPP guidelines recommend treatment intensification if asthma remains uncontrolled, with reassessment occurring in 2 to 6 weeks. Alternatively, de-escalation is recommended if asthma is well-controlled for at least 3 consecutive months. Objective measures, such as spirometry, and self-reported control tools, including the Asthma Control Test (ACT), are utilized. Consider Omalizumab in NAEEP at steps 5 and 6.[21] 

SMART

For individuals with moderate to severe persistent asthma who are already taking low- or medium-dose inhaled corticosteroid, the preferred treatment is a single inhaler with ICS-formoterol (referred to as single maintenance and reliever therapy, or “SMART”). https://www.nhlbi.nih.gov/resources/at-glance-2020-focused-updates-asthma-management-guidelines GINA guidelines recommend the term "MART" (maintenance and reliever therapy) with ICS-formoterol; in some countries, it is referred to as "SMART" (Single-Inhaler Maintenance and Reliever Therapy). The GINA guidelines also use a similar Assess-Adjust-Review cycle, evaluating symptoms (with an ACT score of 20 or greater indicating control), exacerbations, lung function (including forced expiratory volume in 1 second and peak expiratory flow), and biomarkers (such as fractional exhaled nitric oxide exceeding 50 parts per billion [ppb] in adults and adolescents or 35 ppb in children, or blood eosinophils exceeding 300/μL for guiding biologic therapy. GINA guidelines recommend MART (with ICS-formoterol); in some countries, this is referred to as SMART. Consult with an asthma specialist if you require step 4 or higher. Consider consultation at step 3. Specialist consultation is advised in the NAEPP guidelines for step 4 or higher and in the GINA guidelines for steps 4 to 5. Consider biologics in asthma, such as anti-immunoglobulin E, anti-interleukin (IL)-5/IL-5R, anti-IL-4 receptor alpha, and anti-thymic stromal lymphopoietin (Tezepemulab) (see Table. Asthma Management for Individuals Aged 12 or Older).[22][21][22][23]

 Table. Asthma Management for Individuals Aged 12 or Older

Table

GINA Preferred Treatment Daily medium-high dose ICS-LABA + LAMA, andPRN SABA, Consider Omalizumab

GINA, Global Initiative for Asthma; IG, immunoglobulin; IL, interleukin; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; PRN, as needed; SABA, short-acting beta2-agonist; SMART, single maintenance and reliever therapy

Other Issues

Within the last few decades, the benefits of beta-2 agonists on the overall effect against mortality and morbidity have been widely debated. While LABAs have been proven to improve pulmonary function, provide symptomatic relief, and improve quality of life, data suggest that the chronic use of LABAs as a monotherapy approach has led to an overall increase in severe asthma incidences up to hospitalization, intubation, or even mortality.[24][25] Subsequent studies were performed using dual therapy of LABAs and ICS as a treatment for asthma, and compared to monotherapy, there was a decrease in the incidence of severe asthma exacerbations.[5][26]

Current literature continues to support the safety of dual therapy versus monotherapy. In 2017, the Food and Drug Administration approved the safety of dual therapy in asthmatic patients while warning against the use of monotherapy of LABAs. The Global Initiative for COPD, the National Asthma Education and Prevention Program, and many other guidelines agree regarding the use of dual therapy to treat uncontrolled asthma with SABA. Despite the support, it is still unclear whether dual therapy can provide complete protection against the risk of asthma exacerbations historically correlated with single LABA treatment.

SABA overuse was associated with increased rates of mortality and acute exacerbations in patients with asthma.[27] The topic of SABA overuse in previously clinically stable individuals with COPD is a point of discussion, as studies have demonstrated, without conclusive evidence, a worsening of disease severity in this setting. An increase in airway hyperreactivity appears with frequent and consistent use of SABAs, potentially leading to paradoxical airway narrowing.[10] Paradoxical bronchoconstriction is unexpected airway narrowing that occurs despite using beta-agonists; it has been observed with inhaler formulations where excipients may trigger hyperresponsiveness in inflamed airways.[28] SABA overuse is relatively prevalent in the population of asthma and COPD patients. In a study on patients with COPD currently on treatment, 19% were overusing SABAs, and a separate survey of asthmatic patients showed 15.8% overuse of SABAs. In those with COPD, there was an association with increased dyspnea and worsening of quality of life.[29] According to GINA guidelines, the use of long-acting beta-2-adrenergic agonists as monotherapy without inhaled corticosteroids for asthma is associated with an increased risk of asthma-related death.https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf

Enhancing Healthcare Team Outcomes

Given that most patients with COPD and severe asthma will require lifetime treatment, managing treatment with beta-2 agonists in the context of the National Asthma Education and Prevention Program and GOLD guidelines requires a patient-centered approach involving coordination between interprofessional team members. In primary care, study results have shown improvement in the quality of diagnostic and guideline-oriented therapy approaches in settings with a designated respiratory care specialist. Patient outcomes improved under more focused care, characterized by overall decreases in symptoms and a reduction in the use of rescue inhalers. Patients also demonstrated proper inhaler technique more frequently compared to facilities without a respiratory care specialist, and the use of spirometry as a diagnostic tool was more prevalent.[30] Pharmacists can verify dosing, teach proper inhalation and spacer technique, and perform medication reconciliation, alerting the prescriber to any concerns or potential issues that may arise. Nursing can monitor care, reinforce administration counseling, and assess therapeutic effectiveness.

Patients are often from the geriatric population, and coordination between the clinician and a nursing home or community center must ensure medication compliance and adequate outpatient care, particularly in patients with multiple disabilities. Pulmonary rehabilitation, which helps patients regain lost strength and endurance and reintegrate into the community, has improved overall patient quality of life. This approach involves educating patients on coping mechanisms for exacerbations or dyspnea to minimize emotional stress, teaching them proper breathing techniques, the importance of pacing, and making necessary life modifications, along with muscle training. Communication with the patient on correct inhalation techniques, signs of adverse effects, and lifestyle modifications, including smoking cessation, can improve patient outcomes.[30] Consultation with a pulmonologist and a respiratory therapist is often involved in managing patients, especially those with multiple comorbidities. Beta-2 agonist therapy requires an interprofessional team approach, including clinicians, pulmonologists, immunologists, specialty-trained nurses, respiratory therapists, and pharmacists, collaborating across disciplines to achieve optimal patient results.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Billington CK, Ojo OO, Penn RB, Ito S. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther. 2013 Feb;26(1):112-20. [PMC free article: PMC3574867] [PubMed: 22634112]

2.

Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-Adrenergic Agonists. Pharmaceuticals (Basel). 2010 Mar 30;3(4):1016-1044. [PMC free article: PMC4034018] [PubMed: 27713285]

3.

Effa E, Webster A. Pharmacological interventions for the management of acute hyperkalaemia in adults. Nephrology (Carlton). 2017 Jan;22(1):5-6. [PubMed: 28004486]

4.

Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karlíčková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M., TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018 Jul;38(4):1332-1403. [PMC free article: PMC6033155] [PubMed: 29315692]

5.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907-922. [PMC free article: PMC5364009] [PubMed: 28360514]

6.

Dhand R, Hess MW, Yohannes AM. Recalibrating Perceptions and Attitudes Toward Nebulizers versus Inhalers for Maintenance Therapy in COPD: Past as Prologue. Int J Chron Obstruct Pulmon Dis. 2024;19:2571-2586. [PMC free article: PMC11612562] [PubMed: 39629181]

7.

Cazzola M, Calzetta L, Matera MG. β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011 May;163(1):4-17. [PMC free article: PMC3085864] [PubMed: 21232045]

8.

Proudman RGW, Baker JG. A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β₂-Agonists Used for Asthma and COPD. Pharmacol Res Perspect. 2025 Oct;13(5):e70154. [PMC free article: PMC12399788] [PubMed: 40887869]

9.

Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1101-1111. [PubMed: 30261755]

10.

Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S322-8. [PubMed: 12464943]

11.

Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21. [PubMed: 15189956]

12.

Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M. Theophylline and salbutamol in combination in patients with obstructive pulmonary disease and concurrent heart disease: effect on cardiac arrhythmias. J Intern Med. 1989 Oct;226(4):229-34. [PubMed: 2681505]

13.

Park HS, Lee J, Kim H, Woo SD. Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management. Respir Res. 2025 Jan 13;26(1):12. [PMC free article: PMC11730512] [PubMed: 39806413]

14.

Grove A, Lipworth BJ. Tolerance with beta 2-adrenoceptor agonists: time for reappraisal. Br J Clin Pharmacol. 1995 Feb;39(2):109-18. [PMC free article: PMC1364946] [PubMed: 7742147]

15.

Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med. 2005 May;99(5):566-71. [PubMed: 15823453]

16.

Twentyman OP, Higenbottam TW. Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma. Respir Med. 1992 Nov;86(6):471-6. [PubMed: 1361679]

17.

Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198-203. [PubMed: 1357550]

18.

Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000 Jul;162(1):75-80. [PubMed: 10903223]

19.

de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, Casali L, Ferrari M, Nicolini G, Panico MG, Pirina P, Zanolin ME, Cerveri I, Verlato G. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8(5):e62985. [PMC free article: PMC3651288] [PubMed: 23675448]

20.

Figueira Gonçalves JM, García Bello MÁ, Martín Martínez MD, Pérez Méndez LI, García-Talavera I, García Hernández S, Díaz Pérez D, Bethencourt Martín N. The COPD Comorbidome in the Light of the Degree of Dyspnea and Risk of Exacerbation. COPD. 2019 Feb;16(1):104-107. [PubMed: 31032664]

21.

Chipps BE, Murphy KR, Oppenheimer J. 2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S19-S30. [PubMed: 34718214]

22.

Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025 Jan;13(1):23-34. [PubMed: 39549709]

23.

Dubin S, Patak P, Jung D. Update on Asthma Management Guidelines. Mo Med. 2024 Sep-Oct;121(5):364-367. [PMC free article: PMC11482852] [PubMed: 39421468]

24.

Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405-11. [PubMed: 9358137]

25.

Lanes SF, Lanza LL, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med. 1998 Sep;158(3):857-61. [PubMed: 9731017]

26.

Rayner DG, Ferri DM, Guyatt GH, O'Byrne PM, Brignardello-Petersen R, Foroutan F, Chipps B, Sumino K, Perry TT, Nyenhuis S, Oppenheimer J, Israel E, Hoyte F, Rivera-Spoljaric K, McCabe E, Rangel S, Shade LE, Press VG, Hall L, Sue-Wah-Sing D, Melendez A, Orr H, Winders T, Gardner DD, Przywara K, Rank MA, Bacharier LB, Mosnaim G, Chu DK. Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis. JAMA. 2025 Jan 14;333(2):143-152. [PMC free article: PMC11519786] [PubMed: 39465893]

27.

Tsao CL, Chan SY, Lee MH, Hsieh TYJ, Phipatanakul W, Ruran HB, Ma KS. Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis. Allergy. 2025 Jun;80(6):1629-1646. [PMC free article: PMC12186600] [PubMed: 40491263]

28.

Magee JS, Pittman LM, Jette-Kelly LA. Paradoxical Bronchoconstriction with Short-Acting Beta Agonist. Am J Case Rep. 2018 Oct 09;19:1204-1207. [PMC free article: PMC6192384] [PubMed: 30297688]

29.

Fan VS, Gylys-Colwell I, Locke E, Sumino K, Nguyen HQ, Thomas RM, Magzamen S. Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability. Respir Med. 2016 Jul;116:100-6. [PubMed: 27296828]

30.

Hart MK, Millard MW. Approaches to chronic disease management for asthma and chronic obstructive pulmonary disease: strategies through the continuum of care. Proc (Bayl Univ Med Cent). 2010 Jul;23(3):223-9. [PMC free article: PMC2900972] [PubMed: 20671816]

Disclosure: Eric Hsu declares no relevant financial relationships with ineligible companies.

Disclosure: Tushar Bajaj declares no relevant financial relationships with ineligible companies.